Despite encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable difficulty from PBMs. The organizations are typically erecting limitations to reimbursement, including significant cost requirements and PA t